PTNPalatin Technologies, Inc.
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral sma…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Palatin Technologies, Inc. Q3 2026 Earnings Call Summary Moby summary of Palatin Technologies, Inc.'s Q3 2026 earnings call | ||
Palatin Technologies Inc (PTN) Q3 2026 Earnings Call Highlights: Strategic Advances Amidst ... Palatin Technologies Inc (PTN) reports significant revenue growth and strategic partnerships, while navigating increased expenses and development delays. | ||
 Transcript: Palatin Techs Q3 2026 Earnings Conference Call Palatin Techs (AMEX:PTN) held its third-quarter earnings conference call on Wednesday. Below is the complete transcript from the call. Benzinga APIs provide real-time access to earnings call transcripts and financial data. Visit https://www.benzinga.com/apis/ to learn more. Access the full call at https://www.webcaster5.com/Webcast/Page/2953/54002 Summary Palatin Techs reported $3.9 million in collaboration and license revenue for Q3 2026, marking an increase from no revenue in the prior year, p | ||
Palatin Technologies, Inc. Q2 2026 Earnings Call Summary Moby summary of Palatin Technologies, Inc.'s Q2 2026 earnings call | ||
Palatin Technologies Inc (PTN) Q2 2026 Earnings Call Highlights: Strategic Advances Amid Rising ... Despite a significant net loss, Palatin Technologies Inc (PTN) strengthens its financial position with a successful public offering and advances in its obesity treatment pipeline. | ||